These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32316918)

  • 41. Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice.
    Tanaka T; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kaibori M; Hiasa Y; Kudo M; Kumada T; ;
    Hepatol Res; 2022 Sep; 52(9):773-783. PubMed ID: 35633504
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment.
    Chuma M; Yokoo H; Hiraoka A; Ueda K; Yokoyama T; Tsuji K; Shimada N; Uojima H; Kobayashi S; Hattori N; Okubo T; Atsukawa M; Ishikawa T; Takaguchi K; Tsutsui A; Toyoda H; Tada T; Saito Y; Hirose S; Tanaka T; Takeda K; Otani M; Sekikawa Z; Watanabe T; Hidaka H; Morimoto M; Numata K; Kagawa T; Sakamoto M; Kumada T; Maeda S
    Curr Oncol; 2022 May; 29(5):3259-3271. PubMed ID: 35621656
    [TBL] [Abstract][Full Text] [Related]  

  • 43. C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Aoki T; Koizumi Y; Nakamura S; Joko K; Hiasa Y; Kudo M
    Sci Rep; 2022 May; 12(1):8421. PubMed ID: 35589772
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y;
    Cancer Med; 2022 Oct; 11(20):3796-3808. PubMed ID: 35441477
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treating an Intractable Jejunocutaneous Fistula by Endoscopic Metallic Stent Placement: A Case Report of Successful Palliative Endoscopic Treatment in a Case Demonstrating Peritoneal Dissemination with Terminal Stage Gastric Cancer.
    Tanaka H; Ota K; Sugawara N; Iwatsubo T; Kawaguchi S; Mori Y; Nakajima N; Hakoda A; Kojima Y; Inoue Y; Takeuchi T; Higuchi K
    Intern Med; 2022 Nov; 61(22):3343-3347. PubMed ID: 35400702
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y;
    Eur J Gastroenterol Hepatol; 2022 Jun; 34(6):698-706. PubMed ID: 35170529
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis.
    Hatanaka T; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Kumada T; ;
    Hepatol Res; 2022 May; 52(5):462-470. PubMed ID: 35080087
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [A Case of Pancreas Neuroendocrine Carcinoma Achieved Long-Term Survival by Carboplatin plus Etoposide Therapy].
    Okada T; Katada Y; Kitagawa S; Iwamoto R; Kinoshita S; Ueno M; Mineta S; Tanaka H; Kubota H; Higashida M; Sanuki F; Endo S; Yoshimatsu K; Fujiwara Y; Ueno T
    Gan To Kagaku Ryoho; 2021 Dec; 48(13):1813-1815. PubMed ID: 35046339
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Kudo M; ;
    Hepatol Res; 2022 Mar; 52(3):308-316. PubMed ID: 34799975
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case-control study.
    Matsumoto K; Ohfuji S; Abe M; Komori A; Takahashi A; Fujii H; Kawata K; Noritake H; Tadokoro T; Honda A; Asami M; Namisaki T; Ueno M; Sato K; Kakisaka K; Arakawa M; Ito T; Tanaka K; Matsui T; Setsu T; Takamura M; Yasuda S; Katsumi T; Itakura J; Sano T; Tamura Y; Miura R; Arizumi T; Asaoka Y; Uno K; Nishitani A; Ueno Y; Terai S; Takikawa Y; Morimoto Y; Yoshiji H; Mochida S; Ikegami T; Masaki T; Kawada N; Ohira H; Tanaka A
    J Gastroenterol; 2022 Jan; 57(1):19-29. PubMed ID: 34796398
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A potential pathogenic association between periodontal disease and Crohn's disease.
    Imai J; Ichikawa H; Kitamoto S; Golob JL; Kaneko M; Nagata J; Takahashi M; Gillilland MG; Tanaka R; Nagao-Kitamoto H; Hayashi A; Sugihara K; Bishu S; Tsuda S; Ito H; Kojima S; Karakida K; Matsushima M; Suzuki T; Hozumi K; Watanabe N; Giannobile WV; Shirai T; Suzuki H; Kamada N
    JCI Insight; 2021 Dec; 6(23):. PubMed ID: 34710061
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study.
    Hiraoka A; Kumada T; Tada T; Tani J; Kariyama K; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Aoki T; Tanaka T; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Arai T; Okubo T; Imai M; Koizumi Y; Nakamura S; Joko K; Hiasa Y; Kudo M;
    Sci Rep; 2021 Aug; 11(1):16663. PubMed ID: 34404856
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tannin-phytobezoars with Gastric Outlet Obstruction Treated by Dissolution with Administration and Endoscopic Injection of Coca-Cola
    Ota K; Kawaguchi S; Iwatsubo T; Nishida S; Tanaka H; Mori Y; Nakajima N; Hakoda A; Sugawara N; Kojima Y; Takeuchi T; Sakaguchi M; Higuchi K
    Intern Med; 2022 Feb; 61(3):335-338. PubMed ID: 34334573
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib.
    Rapposelli IG; Tada T; Shimose S; Burgio V; Kumada T; Iwamoto H; Hiraoka A; Niizeki T; Atsukawa M; Koga H; Hirooka M; Torimura T; Iavarone M; Tortora R; Campani C; Lonardi S; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Giuseppe Foschi F; Silletta M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Tani J; Nakamura S; Nouso K; Tsutsui A; Nagano T; Tanaka T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y; Rimini M; Ratti F; Aldrighetti L; Cascinu S; Casadei-Gardini A
    Liver Int; 2021 Dec; 41(12):2997-3008. PubMed ID: 34250737
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Survival analyses of elderly gastric cancer patients with or without surgery.
    Endo S; Fujiwara Y; Higashida M; Kubota H; Matsumoto H; Tanaka H; Okada T; Yoshimatsu K; Sugimoto K; Ueno T
    Surg Today; 2022 Jan; 52(1):75-83. PubMed ID: 34014388
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An Adult Case of Congenital Extrahepatic Portosystemic Shunt Successfully Treated with Balloon-occluded Retrograde Transvenous Obliteration.
    Tanaka H; Saijo Y; Tomonari T; Tanaka T; Taniguchi T; Yagi S; Okamoto K; Miyamoto H; Sogabe M; Sato Y; Muguruma N; Tsuneyama K; Sata M; Takayama T
    Intern Med; 2021 Jun; 60(12):1839-1845. PubMed ID: 33456037
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis.
    Tomonari T; Sato Y; Tani J; Hirose A; Ogawa C; Morishita A; Tanaka H; Tanaka T; Taniguchi T; Okamoto K; Sogabe M; Miyamoto H; Muguruma N; Uchida K; Masaki T; Takayama T
    Hepatol Res; 2021 Apr; 51(4):472-481. PubMed ID: 33238074
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study.
    Tada T; Kumada T; Okushin H; Tani J; Takaguchi K; Tsutsui A; Toyoda H; Yasuda S; Dohmen K; Hiraoka A; Michitaka K; Nouso K; Kariyama K; Kim SR; Kim SK; Fujioka S; Mikami S; Watanabe Y; Tamai T; Atsukawa M; Itokawa N; Tanaka H; Tsuji K; Ishikawa T; Imai M; Itobayashi E; Shibata H; Shimada N
    Infect Dis Ther; 2021 Mar; 10(1):269-280. PubMed ID: 33141401
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports.
    Tomonari T; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Okamoto K; Miyamoto H; Muguruma N; Saito Y; Imura S; Bando Y; Shimada M; Takayama T
    Medicine (Baltimore); 2020 Oct; 99(42):e22782. PubMed ID: 33080748
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma.
    Tanaka H; Okamoto K; Sato Y; Tanaka T; Tomonari T; Nakamura F; Fujino Y; Mitsui Y; Miyamoto H; Muguruma N; Morita A; Ikushima H; Takayama T
    J Gastroenterol; 2020 Nov; 55(11):1072-1086. PubMed ID: 32666201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.